Clinical trials: Central Precocious Puberty (CPP)
Central Precocious Puberty (CPP), Puberty Disorders
Spexin and Phoenixin-20 in Girls With Central Precocious Puberty
Central precocious puberty (CPP) is characterized by the early activation of the hypothalamic-pituitary-gonadal axis in girls and may be difficult to distinguish from benign variants such as premature thelarche.
- Conditions
- Central Precocious Puberty (CPP), Puberty Disorders, Puberty, Hypothalamic-Pituitary-Ovarian Axis Dysfunction (Disorder)
- Trial name
- SPX-PNX-CPP-20 (NCT07359092)
- Where
- Turkey (Türkiye)
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Kayseri City Hospital
Central Precocious Puberty, Sexual Precocity
Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls
The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard.
- Trial name
- NCT01278290
- Testing
- Triptorelin acetate and Gonadorelin acetate, Gonadorelin acetate and Triptorelin acetate
- Where
- Argentina
- Volunteers
- 46 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Central Precocious Puberty (CPP)
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a…
- Trial name
- NCT03695237
- Testing
- Leuprolide Acetate (LA)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- AbbVie
CPP
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.
- Trial name
- NEST (NCT06926933)
- Testing
- Eligard® 45 mg
- Where
- 9 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Puberty, Precocious
Study of Lupron Depot In The Treatment of Central Precocious Puberty
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after…
- Trial name
- NCT00660010
- Testing
- Lupron (leuprolide acetate)
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Abbott
Central Precocious Puberty
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study…
- Trial name
- PUPIL (NCT05341115)
- Testing
- Leuprorelin Acetate Depot 3M
- Where
- 5 sites in China
- Volunteers
- 79 people
- Sponsor
- Takeda
Precocious Puberty, Central
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate
- Trial name
- NCT02974270
- Testing
- Leuprolide
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Kyungpook National University Hospital
Central Precocious Puberty
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them.
- Trial name
- PACTURE (NCT05341128)
- Where
- 5 sites in China
- Volunteers
- 1,477 people
- Sponsor
- Takeda
Central Precocious Puberty
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.
- Trial name
- NCT02993926
- Testing
- Enantone, GnRH agonist
- Where
- 6 sites in China
- Volunteers
- 108 people
- Sponsor
- Takeda
Central Precocious Puberty (CPP)
Idiopathic Central Precocious Puberty and Associated Neurodevelopmental Syndromes and Pathologies: Evaluation of Frequency and Comparison of Diagnostic and Developmental Characteristics
Observational, retrosopective, single-centre, non-profit study focused on the frequency of Central Precocious Puberty idiopathic, or associated to Neurodevelopmental Syndromes and Pathologies, and comparison of diagnostic and…
- Trial name
- NCT06720844
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Puberty, Precocious
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
- Trial name
- NCT00635817
- Testing
- Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- Abbott
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Central Precocious Puberty (CPP)
Diagnostic Power of Basal LH Compared to Peak LH After Stimulus Test in the Diagnosis of Central Precocious Puberty
This is an observational, retrospective, single-center study focused on the diagnosis of Central Precocious Puberty in female patients.
- Trial name
- NCT06720623
- Where
- Italy
- Volunteers
- 213 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna